menu
    • menu
    [{"orgOrder":0,"company":"NeuroTherapia","sponsor":"CRU Early Phase Unit Kistarcsa","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"NTRX-07","moa":"Cannabinoid receptor 2 (CB2)","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroTherapia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeuroTherapia \/ CRU Early Phase Unit Kistarcsa","highestDevelopmentStatusID":"8","companyTruncated":"NeuroTherapia \/ CRU Early Phase Unit Kistarcsa"},{"orgOrder":0,"company":"NeuroTherapia","sponsor":"Alzheimer\u2019s Association","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Funding","leadProduct":"NTRX-07","moa":"Cannabinoid receptor 2 (CB2)","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroTherapia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeuroTherapia \/ Alzheimer\u2019s Association","highestDevelopmentStatusID":"8","companyTruncated":"NeuroTherapia \/ Alzheimer\u2019s Association"},{"orgOrder":0,"company":"NeuroTherapia","sponsor":"Cleveland Clinic","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Series B Financing","leadProduct":"NTRX-07","moa":"Cannabinoid receptor 2 (CB2)","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroTherapia","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"NeuroTherapia \/ Cleveland Clinic","highestDevelopmentStatusID":"8","companyTruncated":"NeuroTherapia \/ Cleveland Clinic"},{"orgOrder":0,"company":"NeuroTherapia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"NTRX-07","moa":"Cannabinoid receptor 2 (CB2)","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroTherapia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeuroTherapia \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NeuroTherapia \/ Undisclosed"},{"orgOrder":0,"company":"NeuroTherapia","sponsor":"Brain Trust Accelerator Fund Ii","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Series A Financing","leadProduct":"NTRX-07","moa":"Cannabinoid receptor 2 (CB2)","graph1":"Neurology","graph2":"Phase I","graph3":"NeuroTherapia","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"NeuroTherapia \/ Brain Trust Accelerator Fund Ii","highestDevelopmentStatusID":"6","companyTruncated":"NeuroTherapia \/ Brain Trust Accelerator Fund Ii"},{"orgOrder":0,"company":"NeuroTherapia","sponsor":"Cruint Global Consulting Pte Ltd | Firalis SA | Pharma-Regist Kft.","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"NTRX-07","moa":"Cannabinoid receptor 2 (CB2)","graph1":"Neurology","graph2":"Phase II","graph3":"NeuroTherapia","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeuroTherapia \/ Cruint Global Consulting Pte Ltd | Firalis SA | Pharma-Regist Kft.","highestDevelopmentStatusID":"8","companyTruncated":"NeuroTherapia \/ Cruint Global Consulting Pte Ltd | Firalis SA | Pharma-Regist Kft."},{"orgOrder":0,"company":"NeuroTherapia","sponsor":"Integrium | Orange County Research Center","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"NTRX-07-SDD","moa":"Undisclosed","graph1":"Neurology","graph2":"Phase I","graph3":"NeuroTherapia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"NeuroTherapia \/ Integrium | Orange County Research Center","highestDevelopmentStatusID":"6","companyTruncated":"NeuroTherapia \/ Integrium | Orange County Research Center"}]

    Find Clinical Drug Pipeline Developments & Deals by NeuroTherapia

    Menu

    NeuroTherapia

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            NeuroTherapia

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            NeuroTherapia

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NTRX-07

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Cruint Global Consulting Pte Ltd | Firalis SA | Pharma-Regist Kft.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of NTRX-07 in Participants with Alzheimer's Disease

                            Details : NTRX-07 is a Other Small Molecule drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 10, 2025

                            Lead Product(s) : NTRX-07

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Cruint Global Consulting Pte Ltd | Firalis SA | Pharma-Regist Kft.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            NeuroTherapia

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            NeuroTherapia

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NTRX-07

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NeuroTherapia Gets EMA Approval for Phase 2 Alzheimer’s Disease Trial

                            Details : NTRX-07 is a small orally available molecule that works as a cannabinoid receptor agonist, it is currently being investigated for alzheimer's disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 04, 2025

                            Lead Product(s) : NTRX-07

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            NeuroTherapia

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            NeuroTherapia

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NTRX-07

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Cleveland Clinic

                            Deal Size : $12.3 million

                            Deal Type : Series B Financing

                            DEALS_DEV arrow-down

                            NeuroTherapia Raises $12.3M in the First Close of its Series B Financing

                            Details : NeuroTherapia will use this funding primarily for the continued clinical development of NTRX-07, an orally available cannabinoid receptor agonist, for the treatment of Alzheimer's disease

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 06, 2024

                            Lead Product(s) : NTRX-07

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Cleveland Clinic

                            Deal Size : $12.3 million

                            Deal Type : Series B Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            NeuroTherapia

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            NeuroTherapia

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NTRX-07

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Alzheimer’s Association

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            NeuroTherapia Receives Grant from Alzheimer's Association for its Alzheimer’s Drug

                            Details : The net proceeds will be used for the development of its first-in-class drug, NTRX-07, a novel drug that targets neuroinflammation, for the treatment of Alzheimer's disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            May 08, 2024

                            Lead Product(s) : NTRX-07

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Alzheimer’s Association

                            Deal Size : Undisclosed

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            NeuroTherapia

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            NeuroTherapia

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NTRX-07

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : CRU Early Phase Unit Kistarcsa

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Multiple Dose Study of the Safety and Pharmacokinetics of NTRX-07

                            Details : NTRX-07 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Alzheimer Disease.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 08, 2024

                            Lead Product(s) : NTRX-07

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : CRU Early Phase Unit Kistarcsa

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            NeuroTherapia

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            NeuroTherapia

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NTRX-07

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Brain Trust Accelerator Fund Ii

                            Deal Size : $8.8 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            NeuroTherapia Closes $8.8M Series A Financing Led By Brain Trust Accelerator Fund II

                            Details : NeuroTherapia is currently completing its first-in-human clinical trial using NTRX-07 with funding provided in part by a grant from the Alzheimer's Association. The company will use the Series A funds to finish this work while also undertaking a number o...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 22, 2020

                            Lead Product(s) : NTRX-07

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Brain Trust Accelerator Fund Ii

                            Deal Size : $8.8 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            NeuroTherapia

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed

                            NeuroTherapia

                            U.S.A arrow
                            Bio-Europe Autumn
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : NTRX-07-SDD

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Integrium | Orange County Research Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety and Tolerability of NTRX-07 in Healthy Volunteers

                            Details : NTRX-07-SDD is a drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neuralgia.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            May 05, 2020

                            Lead Product(s) : NTRX-07-SDD

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Integrium | Orange County Research Center

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth